Epstein-Barr virus latent membrane protein 1 induces CD69 expression through activation of nuclear factor-κB

Ishikawa,Chie; Mori,Naoki

doi:10.3892/ijo.2013.1871

Epstein-Barr virus latent membrane protein 1 induces CD69 expression through activation of nuclear factor-κB

Authors:
- Chie Ishikawa
- Naoki Mori
View Affiliations

Affiliations: Transdisciplinary Research Organization for Subtropics and Island Studies, Nishihara, Okinawa 903-0213, Japan, Department of Microbiology and Oncology, Graduate School of Medicine, University of the Ryukyus, Nishihara, Okinawa 903-0215, Japan
Published online on: March 28, 2013 https://doi.org/10.3892/ijo.2013.1871
Pages: 1786-1792

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Latent membrane protein‑1 (LMP-1) of Epstein‑Barr virus (EBV) promotes tumorigenesis. Here, we report that LMP-1 activates the immunoregulatory molecule CD69 gene transcription through a nuclear factor-κB (NF-κB)‑dependent pathway. CD69 expression was upregulated in LMP-1‑expressing EBV-immortalized human B-cell lines and an EBV-positive Burkitt's lymphoma cell line. LMP-1 expression increased CD69 expression at the transcriptional level. CD69 promoter was regulated by LMP-1 activation of NF-κB via the carboxy-terminal activation region 1 and 2. Promoter deletion analysis indicated that two NF-κB binding sites are necessary for activation of the CD69 promoter. Electrophoretic mobility shift analysis demonstrated that LMP-1 activates both NF-κB binding sites in the CD69 promoter. This is the first report of the regulation of CD69 expression by LMP-1, and this novel finding may, thus, represent an important link between the EBV oncoprotein LMP-1 and its critical role in the development of EBV-associated diseases.

View Figures

View References

1.	Epstein MA, Achong BG and Barr YM: Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1:702–703. 1964.PubMed/NCBI
2.	Kieff ED and Rickinson AB: Epstein-Barr virus and its replication. Fields’ virology. Knipe DM and Howley PM: Lippincott Williams & Wilkins; Philadelphia: pp. 2603–2654. 2006
3.	Taylor GS and Blackbourn DJ: Infectious agents in human cancers: lessons in immunity and immunomodulation from gammaherpesviruses EBV and KSHV. Cancer Lett. 305:263–278. 2011. View Article : Google Scholar : PubMed/NCBI
4.	Kaye KM, Izumi KM and Kieff E: Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci USA. 90:9150–9154. 1993. View Article : Google Scholar : PubMed/NCBI
5.	Devergne O, Cahir McFarland ED, Mosialos G, Izumi KM, Ware CF and Kieff E: Role of the TRAF binding site and NF-κB activation in Epstein-Barr virus latent membrane protein 1-induced cell gene expression. J Virol. 72:7900–7908. 1998.
6.	Izumi KM and Kieff ED: The Epstein-Barr virus oncogene product latent membrane protein 1 engages the tumor necrosis factor receptor-associated death domain protein to mediate B lymphocyte growth transformation and activate NF-κB. Proc Natl Acad Sci USA. 94:12592–12597. 1997.PubMed/NCBI
7.	Soni V, Cahir-McFarland E and Kieff E: LMP1 TRAFficking activates growth and survival pathways. Adv Exp Med Biol. 597:173–187. 2007. View Article : Google Scholar : PubMed/NCBI
8.	Schultheiss U, Püschner S, Kremmer E, Mak TW, Engelmann H, Hammerschmidt W and Kieser A: TRAF6 is a critical mediator of signal transduction by the viral oncogene latent membrane protein 1. EMBO J. 20:5678–5691. 2001. View Article : Google Scholar : PubMed/NCBI
9.	Hayden MS and Ghosh S: Shared principles in NF-κB signaling. Cell. 132:344–362. 2008.
10.	Zandi E and Karin M: Bridging the gap: composition, regulation, and physiological function of the IκB kinase complex. Mol Cell Biol. 19:4547–4551. 1999.PubMed/NCBI
11.	Woronicz JD, Gao X, Cao Z, Rothe M and Goeddel DV: IκB kinase-β: NF-κB activation and complex formation with IκB kinase-α and NIK. Science. 278:866–869. 1997.
12.	Lee FS, Peters RT, Dang LC and Maniatis T: MEKK1 activates both IκB kinase α and IκB kinase β. Proc Natl Acad Sci USA. 95:9319–9324. 1998.
13.	Sylla BS, Hung SC, Davidson DM, Hatzivassiliou E, Malinin NL, Wallach D, Gilmore TD, Kieff E and Mosialos G: Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-κB through a pathway that includes the NF-κB-inducing kinase and the IκB kinases IKKα and IKKβ. Proc Natl Acad Sci USA. 95:10106–10111. 1998.PubMed/NCBI
14.	Sánchez-Mateos P and Sánchez-Madrid F: Structure-function relationship and immunochemical mapping of external and intracellular antigenic sites on the lymphocyte activation inducer molecule, AIM/CD69. Eur J Immunol. 21:2317–2325. 1991.
15.	Sant’Angelo DB, Lucas B, Waterbury PG, Cohen B, Brabb T, Goverman J, Germain RN and Janeway CA Jr: A molecular map of T cell development. Immunity. 9:179–186. 1998.
16.	Testi R, D’Ambrosio D, De Maria R and Santoni A: The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells. Immunol Today. 15:479–483. 1994. View Article : Google Scholar : PubMed/NCBI
17.	De la Fuente H, Cibrián D and Sánchez-Madrid F: Immunoregulatory molecules are master regulators of inflammation during the immune response. FEBS Lett. 586:2897–2905. 2012.PubMed/NCBI
18.	Huen DS, Henderson SA, Croom-Carter D and Rowe M: The Epstein-Barr virus latent membrane protein-1 (LMP1) mediates activation of NF-κB and cell surface phenotype via two effector regions in its carboxy-terminal cytoplasmic domain. Oncogene. 10:549–560. 1995.
19.	Floettmann JE and Rowe M: Epstein-Barr virus latent membrane protein-1 (LMP1) C-terminus activation region 2 (CTAR2) maps to the far C-terminus and requires oligomerisation for NF-κB activation. Oncogene. 15:1851–1858. 1997.PubMed/NCBI
20.	López-Cabrera M, Muñoz E, Blázquez MV, Ursa MA, Santis AG and Sánchez-Madrid F: Transcriptional regulation of the gene encoding the human C-type lectin leukocyte receptor AIM/CD69 and functional characterization of its tumor necrosis factor-α-responsive elements. J Biol Chem. 270:21545–21551. 1995.PubMed/NCBI
21.	Castellanos Mdel C, López-Giral S, López-Cabrera M and de Landázuri MO: Multiple cis-acting elements regulate the expression of the early T cell activation antigen CD69. Eur J Immunol. 32:3108–3117. 2002.PubMed/NCBI
22.	Brockman JA, Scherer DC, McKinsey TA, Hall SM, Qi X, Lee WY and Ballard DW: Coupling of a signal response domain in IκBα to multiple pathways for NF-κB activation. Mol Cell Biol. 15:2809–2818. 1995.
23.	McKinsey TA, Brockman JA, Scherer DC, Al-Murrani SW, Green PL and Ballard DW: Inactivation of IκBβ by the Tax protein of human T-cell leukemia virus type 1: a potential mechanism for constitutive induction of NF-κB. Mol Cell Biol. 16:2083–2090. 1996.
24.	Geleziunas R, Ferrell S, Lin X, Mu Y, Cunningham ET Jr, Grant M, Connelly MA, Hambor JE, Marcu KB and Greene WC: Human T-cell leukemia virus type 1 Tax induction of NF-κB involves activation of the IκB kinase α (IKKα) and IKKβ cellular kinases. Mol Cell Biol. 18:5157–5165. 1998.
25.	Iha H, Kibler KV, Yedavalli VRK, Peloponese JM, Haller K, Miyazato A, Kasai T and Jeang K-T: Segregation of NF-κB activation through NEMO/IKKγ by Tax and TNFα: implications for stimulus-specific interruption of oncogenic signaling. Oncogene. 22:8912–8923. 2003.
26.	Muzio M, Ni J, Feng P and Dixit VM: IRAK (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science. 278:1612–1615. 1997. View Article : Google Scholar
27.	Aizawa S, Nakano H, Ishida T, Horie R, Nagai M, Ito K, Yagita H, Okumura K, Inoue J and Watanabe T: Tumor necrosis factor receptor associated factor (TRAF) 5 and TRAF2 are involved in CD30-mediated NFκB activation. J Biol Chem. 272:2042–2045. 1997.PubMed/NCBI
28.	Antalis TM and Godbolt D: Isolation of intact nuclei from hematopoietic cell types. Nucl Acids Res. 19:43011991. View Article : Google Scholar : PubMed/NCBI
29.	Dewan MZ, Tomita M, Katano H and Yamamoto N, Ahmed S, Yamamoto M, Sata T, Mori N and Yamamoto N: An HIV protease inhibitor, ritonavir targets the nuclear factor-kappaB and inhibits the tumor growth and infiltration of EBV-positive lymphoblastoid B cells. Int J Cancer. 124:622–629. 2009. View Article : Google Scholar : PubMed/NCBI
30.	Xu Z-G, Iwatsuki K, Oyama N, Ohtsuka M, Satoh M, Kikuchi S, Akiba H and Kaneko F: The latency pattern of Epstein-Barr virus infection and viral IL-10 expression in cutaneous natural killer/T-cell lymphomas. Br J Cancer. 84:920–925. 2001. View Article : Google Scholar : PubMed/NCBI
31.	Baeuerle PA: The inducible transcription activator NF-κB: regulation by distinct protein subunits. Biochim Biophys Acta. 1072:63–80. 1991.
32.	Hodge G, Hodge S, Han P and Haslam R: Multiple leucocyte activation markers to detect neonatal infection. Clin Exp Immunol. 135:125–129. 2004. View Article : Google Scholar : PubMed/NCBI
33.	Böhler T, Walcher J, Hölzl-Wenig G, Schnitzler P, Geiss M, Buchholz B, Linde R, Rütschle H and Debatin K-M: Expression of CD69 on T-cells from HIV-1-infected children and adolescents increases with increasing viral load. Eur J Pediatr. 158:638–644. 1999.PubMed/NCBI
34.	Iwashiro M, Messer RJ, Peterson KE, Stromnes IM, Sugie T and Hasenkrug KJ: Immunosuppression by CD4⁺ regulatory T cells induced by chronic retroviral infection. Proc Natl Acad Sci USA. 98:9226–9230. 2001.
35.	Vega-Ramos J, Alari-Pahissa E, Valle JD, Carrasco-Marín E, Esplugues E, Borràs M, Martínez-A C and Lauzurica P: CD69 limits early inflammatory diseases associated with immune response to Listeria monocytogenes infection. Immunol Cell Biol. 88:707–715. 2010. View Article : Google Scholar : PubMed/NCBI
36.	Esplugues E, Sancho D, Vega-Ramos J, Martínez C, Syrbe U, Hamann A, Engel P, Sánchez-Madrid F and Lauzurica P: Enhanced antitumor immunity in mice deficient in CD69. J Exp Med. 197:1093–1106. 2003. View Article : Google Scholar : PubMed/NCBI
37.	Sancho D, Gómez M, Viedma F, Esplugues E, Gordón-Alonso M, García-López MA, de la Fuente H, Martínez-A C, Lauzurica P and Sánchez-Madrid F: CD69 downregulates autoimmune reactivity through active transforming growth factor-β production in collagen-induced arthritis. J Clin Invest. 112:872–882. 2003.PubMed/NCBI
38.	Zhao Q, Kuang D-M, Wu Y, Xiao X, Li X-F, Li T-J and Zheng L: Activated CD69⁺ T cells foster immune privilege by regulating IDO expression in tumor-associated macrophages. J Immunol. 188:1117–1124. 2012.